Last Price$112.9(4.5%)
Market Cap$13.8B
P/EBITDA LTM
16.7x
5Y avg
14.7x
Medical - Diagnostics & Research industry
median
(0.8x)
Stock quality & Intrinsic value
7/10
0.1% undervalued
Revvity, Inc. P/EBITDA LTM
Annual
Quarterly
Daily
Crunching data... Almost there!
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/EBITDA LTM | 12.2x | 9.9x | 12.7x | 5.7x | 10.7x | 11.1x | 8.5x | 14.8x | 20.0x | 12.2x | 17.0x | 14.0x | 19.4x | 17.3x | 18.1x | 18.8x | 14.1x | 12.3x | 15.0x | 16.7x |
Overvalued or undervalued?
Check the intrinsic value for RVTY
and see if it's the right time to invest.
Revvity, Inc. (RVTY) P/EBITDA LTM comparison analysis
General
LTM P/EBITDA LTM
OTHER METRICS
Company name
Revenue growth
EPS growth
Net Income margin
Revvity, Inc.RVTY
16.1x
0.2%
(58.6%)
9.8%
Median Peer Set
18.6x
2.1%
4.0%
15.6%
IDEXX Laboratories, Inc.IDXX
28.0x
6.5%
6.1%
22.8%
Waters CorporationWAT
22.1x
0.1%
(1.1%)
21.6%
Danaher CorporationDHR
22.0x
(0.1%)
(17.9%)
16.3%
Mettler-Toledo International Inc.MTD
21.4x
2.2%
12.7%
22.3%
Agilent Technologies, Inc.A
19.9x
(4.7%)
5.2%
19.8%
Thermo Fisher Scientific Inc.TMO
17.3x
0.1%
6.8%
14.8%
Quest Diagnostics IncorporatedDGX
10.0x
6.7%
2.8%
8.8%
IQVIA Holdings Inc.IQV
9.8x
2.8%
2.4%
8.9%
ICON Public Limited CompanyICLR
8.7x
2.0%
28.7%
9.6%
Natera, Inc.NTRA
(124.4x)
56.7%
(59.5%)
(11.2%)
RVTY key stats
USD
Millions
Billions
Annual
Quarterly
Trailing
Key stats
Income statement
Balance sheet
Cash Flow Statement
Valuation
Ratios
Per share
Per employee
Dividends & Yields
| Dec'05 | Dec'06 | Dec'07 | Dec'08 | Dec'09 | Dec'10 | Dec'11 | Dec'12 | Dec'13 | Dec'14 | Dec'15 | Dec'16 | Dec'17 | Dec'18 | Dec'19 | Dec'20 | Dec'21 | Dec'22 | Dec'23 | Dec'24 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
% growth | 1,473.8 (12.6%) | 1,546.4 4.9% | 1,787.3 15.6% | 1,937.5 8.4% | 1,812.2 (6.5%) | 1,704.3 (6.0%) | 1,921.3 12.7% | 2,115.2 10.1% | 2,166.2 2.4% | 2,237.2 3.3% | 2,262.4 1.1% | 2,115.5 (6.5%) | 2,257.0 6.7% | 2,778.0 23.1% | 2,883.7 3.8% | 3,782.7 31.2% | 5,067.2 34.0% | 3,311.8 (34.6%) | 2,750.6 (16.9%) | 2,755.0 0.2% |
| Cost of Goods Sold (COGS) | 859.3 | 918.3 | 1,062.6 | 1,107.4 | 1,032.4 | 945.7 | 1,070.7 | 1,152.0 | 1,189.3 | 1,232.6 | 1,237.9 | 1,102.2 | 1,184.0 | 1,437.1 | 1,487.6 | 1,672.9 | 2,215.9 | 1,322.0 | 1,210.9 | 1,217.4 |
% margin | 614.5 41.7% | 628.1 40.6% | 724.7 40.5% | 830.1 42.8% | 779.8 43.0% | 758.6 44.5% | 850.6 44.3% | 963.2 45.5% | 977.0 45.1% | 1,004.6 44.9% | 1,024.5 45.3% | 1,013.4 47.9% | 1,073.0 47.5% | 1,340.9 48.3% | 1,396.1 48.4% | 2,109.9 55.8% | 2,851.3 56.3% | 1,989.8 60.1% | 1,539.7 56.0% | 1,537.7 55.8% |
| Operating Expenses | 451.3 | 478.3 | 540.7 | 630.9 | 612.0 | 586.1 | 744.4 | 765.4 | 718.9 | 780.5 | 724.8 | 725.2 | 755.6 | 1,005.9 | 1,004.7 | 1,123.3 | 1,502.5 | 1,247.1 | 1,239.1 | 1,190.9 |
| Research & Development Expenses (R&D) | 87.4 | 99.7 | 111.6 | 108.1 | 107.3 | 95.4 | 115.8 | 132.6 | 133.0 | 121.1 | 125.9 | 124.3 | 139.4 | 194.0 | 189.3 | 205.4 | 275.0 | 221.6 | 216.6 | 196.8 |
| Selling, General & Administrative Expenses (SG&A) | 365.5 | 376.8 | 444.4 | 522.9 | 504.7 | 490.7 | 628.6 | 632.7 | 585.9 | 659.3 | 598.8 | 600.9 | 616.2 | 811.9 | 815.3 | 917.9 | 1,227.5 | 1,025.5 | 1,022.6 | 994.1 |
% margin | 234.3 15.9% | 153.4 9.9% | 168.2 9.4% | 193.0 10.0% | 147.6 8.1% | 153.6 9.0% | 89.7 4.7% | 195.7 9.3% | 217.4 10.0% | 210.7 9.4% | 286.1 12.6% | 283.1 13.4% | 304.8 13.5% | 323.9 11.7% | 362.0 12.6% | 978.6 25.9% | 1,332.4 26.3% | 742.7 22.4% | 300.6 10.9% | 346.7 12.6% |
| Interest Income | 0.0 | 0.0 | 0.0 | 4.0 | 1.0 | 0.8 | 1.9 | 0.7 | 0.7 | 0.7 | 0.7 | 0.7 | 2.6 | 1.1 | 1.5 | 1.0 | 2.2 | 3.6 | 72.1 | 73.2 |
| Interest Expense | 0.0 | 0.0 | 41.7 | 82.1 | 17.2 | 15.9 | 24.8 | 45.8 | 49.9 | 36.3 | 38.0 | 41.5 | 43.9 | 67.0 | 63.6 | 49.7 | 102.1 | 104.0 | 98.8 | 96.3 |
| Pre-tax Income | 66.7 | 150.7 | 151.3 | 147.4 | 130.7 | 162.0 | 62.9 | 50.6 | 153.3 | 169.6 | 244.0 | 244.1 | 296.7 | 257.7 | 237.1 | 906.4 | 1,279.9 | 651.8 | 183.0 | 316.1 |
% effective tax rate | 0.1 0.2% | 32.4 21.5% | 17.5 11.5% | 21.2 14.4% | 37.9 29.0% | 26.1 16.1% | 62.8 99.7% | (17.9) (35.3%) | (12.2) (8.0%) | 8.4 5.0% | 31.3 12.8% | 28.4 11.6% | 139.8 47.1% | 20.2 7.8% | 9.4 4.0% | 178.3 19.7% | 347.6 27.2% | 129.2 19.8% | 3.5 1.9% | 33.1 10.5% |
% margin | 66.5 4.5% | 119.6 7.7% | 131.7 7.4% | 126.4 6.5% | 85.6 4.7% | 135.9 8.0% | 0.2 0.0% | 69.9 3.3% | 167.2 7.7% | 157.8 7.1% | 212.4 9.4% | 234.3 11.1% | 156.9 7.0% | 237.9 8.6% | 227.6 7.9% | 727.9 19.2% | 943.2 18.6% | 569.2 17.2% | 693.1 25.2% | 270.4 9.8% |
| EPS | 0.51 | 0.96 | 1.11 | 1.07 | 0.74 | 1.16 | 0.00 | 0.61 | 1.49 | 1.40 | 1.89 | 2.14 | 1.43 | 2.15 | 2.05 | 6.53 | 8.12 | 4.51 | 5.56 | 2.30 |
| Diluted EPS | 0.51 | 0.95 | 1.09 | 1.07 | 0.73 | 1.15 | 0.00 | 0.61 | 1.47 | 1.39 | 1.87 | 2.12 | 1.42 | 2.13 | 2.04 | 6.49 | 8.08 | 4.50 | 5.55 | 2.20 |
% margin | 287.6 19.5% | 219.2 14.2% | 264.9 14.8% | 262.6 13.6% | 200.9 11.1% | 267.0 15.7% | 200.1 10.4% | 223.2 10.6% | 331.7 15.3% | 322.6 14.4% | 378.6 16.7% | 406.0 19.2% | 424.6 18.8% | 518.8 18.7% | 609.6 21.1% | 1,202.6 31.8% | 1,726.6 34.1% | 1,300.2 39.3% | 713.6 25.9% | 848.0 30.8% |
Discover more Stock Ideas
Undervalued stocks right now
Discover the top 20 best undervalued stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 32.1%
S&P Outperformance 19.1%
Next 3M Predicted Return 20.3%
Undervalued growth stocks
Discover the top 20 best undervalued large-cap growth stocks to buy for Mar 2025, listed on the Nasdaq or NYSE.
3M Return 35.3%
S&P Outperformance 22.3%
Next 3M Predicted Return 26.8%
Undervalued dividend stocks
Discover the top 20 best undervalued high-yield dividend stock that offers both growth potential and attractive dividend returns for Mar 2025.
3M Return 28.4%
S&P Outperformance 15.4%
Next 3M Predicted Return 16.9%
FAQ
1) What is Revvity, Inc.'s P/EBITDA LTM?
As of today, Microsoft Corp's last 12-month P/EBITDA LTM is 16.7x, based on the financial report for Dec 27, 2024 (Q4’2024). The average annual P/EBITDA LTM for Revvity, Inc. have been 13.9x over the past three years, and 15.4x over the past five years.
2) Is Revvity, Inc.'s P/EBITDA LTM Good?
As of today, Revvity, Inc.'s P/EBITDA LTM is 16.7x, which is higher than industry median of (0.8x). It indicates that Revvity, Inc.'s P/EBITDA LTM is Bad.